AOD-9604 vs MOTS-C: Molecular Structure, Mechanisms, and Research Differences

AOD-9604 and MOTS-C are two peptides investigated in scientific research involving metabolism, cellular signaling, and energy regulation. Although both compounds have attracted attention in metabolic research, they differ significantly in their molecular origins, amino acid structures, and proposed biological mechanisms.

AOD-9604 is a synthetic fragment of human growth hormone (HGH). Researchers originally developed it to investigate whether certain metabolic activities associated with growth hormone could be studied separately from its broader growth-related functions.

MOTS-C, on the other hand, is a naturally occurring mitochondrial-derived peptide encoded by mitochondrial DNA. It has been investigated for its potential role in cellular energy balance, metabolic stress responses, and signaling pathways involving AMP-activated protein kinase (AMPK).

Interestingly, both peptides contain 16 amino acids, but their sequences and biological origins are entirely different.

In this AOD-9604 vs MOTS-C comparison, we examine their molecular structures, mechanisms of action, laboratory research applications, and scientific evidence.

What Is the Difference Between AOD-9604 and MOTS-C?

The primary difference between AOD-9604 and MOTS-C is their molecular origin and the metabolic pathways investigated in research.

AOD-9604 is a modified fragment of human growth hormone. It was developed as an experimental compound to investigate lipid metabolism, including processes associated with fat breakdown and storage.

MOTS-C is a mitochondrial-derived signaling peptide. Researchers have investigated its interactions with cellular energy-sensing pathways, particularly AMPK-related signaling.

In simple terms, AOD-9604 was designed to investigate selected growth hormone-associated metabolic activities, while MOTS-C is studied as a mitochondrial signaling molecule involved in energy regulation.

AOD-9604 vs MOTS-C: Quick Comparison

Although both compounds are associated with metabolic research, they should not be considered functionally equivalent.

What Is AOD-9604 Peptide?

AOD-9604, also known as Anti-Obesity Drug 9604, is a synthetic peptide containing 16 amino acid residues.

It is derived from the C-terminal region of human growth hormone, specifically residues corresponding to HGH 177–191, with an additional tyrosine residue at the N-terminus.

Human growth hormone is a protein hormone containing 191 amino acids.

Because the complete hormone influences multiple biological processes, researchers investigated whether smaller regions could exhibit selected biological activities independently.

AOD-9604 emerged from this research.

Early experimental studies focused on lipid metabolism and fat-cell signaling. Researchers examined whether the peptide could influence metabolic pathways without reproducing the full range of growth hormone activity.

However, larger human clinical studies did not establish a significant weight-loss benefit.

Today, AOD-9604 remains an investigational compound rather than an FDA-approved treatment.

For additional background on its molecular properties, see Orion Peptides’ AOD-9604 technical reference.

What Is MOTS-C Peptide?

MOTS-C stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c.

It is a naturally occurring peptide containing 16 amino acids and is encoded by a short open reading frame within the mitochondrial genome.

Mitochondria are cellular organelles responsible for many processes involved in energy production and metabolic regulation.

In addition to their role in cellular energy metabolism, mitochondria can participate in intracellular signaling.

MOTS-C is one of several mitochondrial-derived peptides investigated for their signaling functions.

The compound was described in a landmark 2015 study published in Cell Metabolism.

Researchers reported that MOTS-C influenced metabolic pathways involving folate metabolism, purine biosynthesis, and AMPK activation.

These observations contributed to interest in mitochondrial-derived peptides as signaling molecules.

However, most mechanistic findings originate from laboratory and animal studies. Their relevance to clinical applications remains under investigation.

Researchers can review Orion Peptides’ MOTS-C 10mg research peptide for compound-specific molecular information and analytical documentation.

AOD-9604 vs MOTS-C: Molecular Structure

Although both peptides contain 16 amino acids, their molecular sequences and structural features differ substantially.

AOD-9604 Molecular Structure

AOD-9604 has the following amino acid sequence:

YLRIVQCRSVEGSCGF

Its molecular formula is C₇₈H₁₂₃N₂₃O₂₃S₂, with an approximate molecular weight of 1,815.1 daltons.

The peptide contains two cysteine residues that form an intramolecular disulfide bond.

This bond creates a constrained region within the peptide structure.

AOD-9604 also contains an additional N-terminal tyrosine residue that distinguishes it from the corresponding unmodified growth hormone fragment.

These features are relevant to the peptide’s molecular conformation and analytical characterization.

MOTS-C Molecular Structure

MOTS-C has the amino acid sequence:

MRWQEMGYIFYPRKLR

Its approximate molecular weight is 2,174.6 daltons.

Unlike AOD-9604, the MOTS-C sequence does not contain cysteine residues and therefore cannot form an intramolecular cysteine disulfide bridge.

Its molecular architecture is distinct from that of the growth hormone-derived AOD-9604 peptide.

MOTS-C is encoded within mitochondrial DNA rather than being derived from a conventional nuclear-encoded growth hormone protein.

This unique genetic origin makes MOTS-C relevant to studies involving mitochondrial genetics and peptide signaling.

Why Do These Structural Differences Matter?

The biological properties of peptides depend partly on their amino acid sequences and molecular structures.

AOD-9604 contains a modified growth hormone fragment with a disulfide bond.

MOTS-C contains a distinct mitochondrial-encoded amino acid sequence without the same structural bridge.

These differences affect how researchers classify the compounds and investigate their potential molecular interactions.

Importantly, the fact that both contain 16 amino acids does not mean they act through identical signaling mechanisms.

AOD-9604 vs MOTS-C: Mechanism of Action

The mechanism of action of AOD-9604 vs MOTS-C is one of their most significant scientific differences.

AOD-9604 has been investigated for effects on lipid metabolism.

MOTS-C has been investigated for its interactions with cellular energy metabolism, particularly AMPK-associated pathways.

How Does AOD-9604 Work?

Early AOD-9604 studies focused on metabolic processes associated with adipose tissue.

Several experimental mechanisms were investigated.

1. Lipolysis

Lipolysis is the process through which stored triglycerides are broken down into fatty acids and glycerol.

Some animal studies reported changes in lipid metabolism after experimental exposure to AOD-9604.

These findings suggested that selected regions of human growth hormone might contribute to metabolic activity.

However, preclinical findings cannot independently establish meaningful effects in humans.

2. Lipogenesis

Lipogenesis involves the synthesis and storage of lipids.

Researchers investigated whether AOD-9604 influenced pathways associated with fat accumulation.

Early results helped establish the scientific rationale for further development of the compound.

Nevertheless, later human research did not confirm significant clinical weight-loss efficacy.

3. Beta-Adrenergic Signaling

Some experimental investigations examined whether beta-adrenergic signaling pathways contributed to the observed metabolic activity of AOD-9604.

These studies provided additional information about potential mechanisms.

However, a definitive primary molecular receptor for AOD-9604 has not been established.

For further discussion, read Orion Peptides’ article How AOD-9604 Works.

How Does MOTS-C Work?

MOTS-C is studied through a different set of biological mechanisms.

Early research identified its interactions with cellular pathways involved in energy metabolism.

1. Folate and Purine Metabolism

The 2015 Cell Metabolism study reported that MOTS-C influenced folate metabolism and de novo purine biosynthesis.

These pathways contribute to important cellular functions, including nucleotide production and metabolic regulation.

Changes in these pathways can influence how cells respond to energy-related conditions.

2. AMPK Signaling

AMP-activated protein kinase, commonly called AMPK, is an important cellular energy sensor.

It participates in regulating metabolic activity when cells experience changes in energy availability.

Early MOTS-C research reported activation of AMPK-associated signaling in experimental systems.

These findings suggested that the peptide could participate in mechanisms linking mitochondrial signaling with broader metabolic regulation.

However, the findings do not establish that MOTS-C produces clinically meaningful metabolic benefits in humans.

3. Cellular Stress Responses

Researchers have also investigated MOTS-C in relation to cellular stress.

Experimental findings suggest that mitochondrial-derived peptides may participate in signaling pathways that help cells respond to changes in metabolic conditions.

Studies have examined MOTS-C in contexts involving mitochondrial communication, stress adaptation, and gene regulation.

These areas remain active subjects of scientific investigation.

Scientific reference: Lee et al., Cell Metabolism (2015).

Does AOD-9604 Activate AMPK Like MOTS-C?

AMPK activation is an important part of the experimental literature surrounding MOTS-C.

The same conclusion should not automatically be applied to AOD-9604.

MOTS-C has been investigated in experimental systems where AMPK-related signaling was observed.

AOD-9604 research has focused more directly on growth hormone fragment activity and lipid-related pathways.

Although multiple metabolic pathways may interact within a biological system, there is insufficient evidence to classify AOD-9604 as having the same established AMPK-related mechanism as MOTS-C.

Therefore, these peptides should be studied according to their individual experimental evidence rather than treated as interchangeable metabolic compounds.

AOD-9604 vs MOTS-C in Metabolic Research

Both peptides have attracted scientific interest because of their potential relationships with metabolism.

However, the type and strength of available evidence differ.

AOD-9604 Research Findings

Early AOD-9604 investigations involved laboratory experiments and animal models.

Some studies reported changes in lipid-related processes, leading researchers to investigate the compound further.

AOD-9604 subsequently advanced into human clinical trials.

One of the largest was the OPTIONS trial conducted by Metabolic Pharmaceuticals.

The study enrolled 536 adults with obesity.

The investigators evaluated AOD-9604 against placebo while participants followed a structured diet and exercise program.

The study did not demonstrate a statistically significant improvement in weight loss compared with placebo.

Following the unsuccessful results, development of AOD-9604 as an obesity treatment was discontinued.

The FDA subsequently reviewed the available evidence and concluded that clinical effectiveness for obesity had not been established.

Scientific reference: FDA AOD-9604 Scientific Review.

MOTS-C Research Findings

MOTS-C was first characterized in a 2015 study published in Cell Metabolism.

The researchers investigated the peptide’s potential role in metabolic homeostasis and energy-related signaling.

In animal models, MOTS-C administration was associated with changes in insulin sensitivity and metabolic outcomes under specific experimental conditions.

The study also reported interactions with folate metabolism, purine biosynthesis, and AMPK signaling.

Subsequent investigations expanded interest in MOTS-C to other areas of mitochondrial biology.

However, these observations should not be interpreted as established clinical benefits.

There is insufficient human clinical evidence to conclude that commercially supplied MOTS-C produces reliable therapeutic outcomes.

Comparing the Research Evidence

The research evidence should be interpreted according to the specific experimental models and clinical outcomes studied.

AOD-9604 vs MOTS-C: Which Is More Relevant to Mitochondrial Research?

MOTS-C has a more direct connection to mitochondrial biology because it is encoded by the mitochondrial genome.

Its discovery contributed to understanding how mitochondria may influence cellular signaling beyond their conventional role in energy production.

Researchers have investigated MOTS-C in relation to metabolic regulation, stress responses, and communication between mitochondria and other cellular compartments.

AOD-9604 has a different scientific origin.

It was designed from a region of human growth hormone and investigated primarily in relation to lipid metabolism.

Although lipid metabolism and mitochondrial energy processes are biologically connected, this does not make AOD-9604 a mitochondrial-derived peptide.

For research focused specifically on mitochondrial-encoded signaling molecules, MOTS-C is the more directly relevant subject.

For investigations of growth hormone fragment activity, AOD-9604 represents a distinct research model.

Laboratory Analysis of AOD-9604 and MOTS-C

Accurate compound identification is an important part of reproducible peptide research.

Because AOD-9604 and MOTS-C differ in molecular structure, their analytical properties are also different.

HPLC Analysis

High-performance liquid chromatography is commonly used to separate components in peptide preparations.

It can provide information about chromatographic purity and the presence of detectable impurities.

However, a high chromatographic purity percentage does not independently confirm the correct amino acid sequence.

Mass Spectrometry

Mass spectrometry can help identify molecular masses consistent with the expected compounds.

AOD-9604 has an approximate molecular weight of 1,815.1 daltons.

MOTS-C has an approximate molecular weight of 2,174.6 daltons.

These different masses can help distinguish the two compounds during analytical characterization.

Additional testing may be needed to confirm structural details.

Certificates of Analysis

A Certificate of Analysis can document results for a particular batch of research material.

Depending on the test program, a COA may report identity, purity, assay results, and additional quality-control measurements.

Orion Peptides provides batch-related analytical information through its compound pages and COA library.

Researchers should review the specific methods and reported results rather than assume that all COAs provide identical levels of verification.

AOD-9604 and MOTS-C Research Materials at Orion Peptides

Orion Peptides lists both AOD-9604 and MOTS-C as laboratory research materials.

Researchers reviewing these compounds can find information about their labeled quantities, molecular characteristics, and available analytical documentation through the following compound pages.

The labeled quantities do not represent recommended doses for human or veterinary administration.

These compounds are intended strictly for laboratory and scientific research.

Are AOD-9604 and MOTS-C FDA-Approved?

Neither AOD-9604 nor MOTS-C is FDA-approved for therapeutic use.

AOD-9604 Regulatory Status

AOD-9604 was investigated as a potential obesity-related drug.

However, its clinical development program did not demonstrate significant weight-loss efficacy in a major trial.

The FDA has reviewed available research and identified limitations in both effectiveness and safety evidence.

MOTS-C Regulatory Status

MOTS-C remains an investigational peptide.

Although laboratory and animal research has explored its involvement in cellular energy regulation, it has not received FDA approval as a treatment.

Neither the discovery of a naturally occurring peptide nor promising animal research is sufficient to establish clinical safety or effectiveness.

Commercial research-grade compounds should not be confused with approved pharmaceutical formulations.

Frequently Asked Questions About AOD-9604 vs MOTS-C

What is the main difference between AOD-9604 and MOTS-C?

AOD-9604 is a synthetic fragment analog of human growth hormone, while MOTS-C is a naturally occurring mitochondrial-derived peptide. Their molecular origins and investigated signaling pathways are different.

Are AOD-9604 and MOTS-C the same peptide?

No. Although both contain 16 amino acids, they have different sequences, molecular weights, and structural characteristics.

Does AOD-9604 activate AMPK like MOTS-C?

AMPK-related signaling has been reported in experimental MOTS-C research. Equivalent AMPK activation has not been established as the primary mechanism of AOD-9604.

What is MOTS-C peptide?

MOTS-C is a 16-amino-acid peptide encoded by mitochondrial DNA and investigated for its role in metabolic signaling and cellular energy regulation.

What is AOD-9604 peptide?

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone developed for research involving lipid metabolism and related biological pathways.

Are AOD-9604 and MOTS-C involved in fat metabolism?

Both compounds have been investigated in metabolic research, but their molecular mechanisms differ. Experimental findings do not establish that either produces reliable clinical fat-loss effects.

Which peptide is associated with mitochondrial signaling?

MOTS-C is directly associated with mitochondrial signaling because it is encoded by the mitochondrial genome.

Is MOTS-C FDA-approved?

No. MOTS-C is not FDA-approved for any therapeutic indication.

Is AOD-9604 FDA-approved?

No. AOD-9604 is not FDA-approved for therapeutic use.

Can AOD-9604 and MOTS-C be considered interchangeable?

No. The two compounds have different origins, structures, investigated biological mechanisms, and research evidence.

Conclusion

The comparison of AOD-9604 vs MOTS-C highlights how two peptides containing the same number of amino acids can have very different molecular origins and biological research applications.

AOD-9604 is a modified fragment of human growth hormone investigated primarily for effects on lipid metabolism.

MOTS-C is a mitochondrial-derived peptide investigated for its involvement in cellular energy regulation, metabolic stress responses, and AMPK-associated signaling.

Although both compounds have appeared in metabolic research, their mechanisms are not interchangeable and neither has demonstrated sufficient evidence for FDA-approved therapeutic use.

For researchers, these differences illustrate the importance of understanding peptide structure, genetic origin, molecular signaling pathways, and the limitations of available experimental evidence.

Research Use Disclaimer: This article is intended for scientific and educational purposes only. AOD-9604 and MOTS-C are investigational compounds and are not FDA-approved for therapeutic indications. Research-grade peptides are not intended for human or veterinary consumption, diagnosis, treatment, or clinical use.

Scientific References

1. Lee C et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. https://doi.org/10.1016/j.cmet.2015.02.009
2. Heffernan MA et al. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice. Endocrinology. https://doi.org/10.1210/endo.142.12.8522
3. U.S. Food and Drug Administration. (2024). AOD-9604 Scientific Review. https://www.fda.gov/media/183584/download
4. U.S. Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee: AOD-9604 Clinical Evidence Review. https://www.fda.gov/media/183891/download